Embecta Corp (EMBC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Embecta Corp stock (EMBC) is currently trading at $9.00. Embecta Corp PE ratio is 3.77. Embecta Corp PS ratio (Price-to-Sales) is 0.49. Analyst consensus price target for EMBC is $16.67. WallStSmart rates EMBC as Hold.
- EMBC PE ratio analysis and historical PE chart
- EMBC PS ratio (Price-to-Sales) history and trend
- EMBC intrinsic value — DCF, Graham Number, EPV models
- EMBC stock price prediction 2025 2026 2027 2028 2029 2030
- EMBC fair value vs current price
- EMBC insider transactions and insider buying
- Is EMBC undervalued or overvalued?
- Embecta Corp financial analysis — revenue, earnings, cash flow
- EMBC Piotroski F-Score and Altman Z-Score
- EMBC analyst price target and Smart Rating
Embecta Corp
📊 No data available
Try selecting a different time range
EMBC Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Embecta Corp (EMBC)
EMBC trades at a significant discount to its Graham intrinsic value of $110.45, offering a 91% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Embecta Corp (EMBC) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, price/sales, eps growth. Concerns around revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Embecta Corp (EMBC) Key Strengths (4)
Paying less than $1 for every $1 of annual revenue
Earnings per share surging 82.70% year-over-year
101.87% of shares held by major funds and institutions
Strong operational efficiency: $29 kept per $100 revenue
Supporting Valuation Data
Embecta Corp (EMBC) Areas to Watch (4)
Revenue declining -0.30%, a shrinking business
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Decent profitability, keeps $13 per $100 revenue
Embecta Corp (EMBC) Detailed Analysis Report
Overall Assessment
This company scores 55/100 in our Smart Analysis, earning a C grade. Out of 8 metrics analyzed, 4 register as strengths (avg 9.5/10) while 4 fall into concern territory (avg 4.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, EPS Growth, Institutional Own.. Valuation metrics including Price/Sales (0.49) suggest the stock is attractively priced. Profitability is solid with Operating Margin at 29.20%. Growth metrics are encouraging with EPS Growth at 82.70%.
The Bear Case
The primary concerns are Revenue Growth, Market Cap, Price/Book. Some valuation metrics including Price/Book (2.61) suggest expensive pricing. Growth concerns include Revenue Growth at -0.30%, which may limit upside. Profitability pressure is visible in Profit Margin at 12.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at 29.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -0.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Price/Sales, EPS Growth) and negatives (Revenue Growth, Market Cap). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EMBC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EMBC's Price-to-Sales ratio of 0.49x trades 48% below its historical average of 0.93x (4th percentile). The current valuation is 72% below its historical high of 1.73x set in Nov 2022, and 2% above its historical low of 0.48x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.6x as trailing revenue scaled faster than the stock price.
Compare EMBC with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Embecta Corp (EMBC) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Embecta Corp faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 1.1B with 30% decline year-over-year. Profit margins of 12.9% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 17M in free cash flow and 17M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of -2.32 indicates a conservative balance sheet with 204M in cash.
Revenue contracted 30% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Margin expansion: can Embecta Corp push profit margins above 15% as the business scales?
Dividend sustainability with a current yield of 6.6%. Watch payout ratio and free cash flow coverage.
Debt management: total debt of 1.4B is significantly higher than cash (204M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Embecta Corp.
Bottom Line
Embecta Corp faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(6 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:23:07 AM
About Embecta Corp(EMBC)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Embecta Corp (EMBC) is a leading global medical technology firm dedicated to advancing diabetes management through its cutting-edge insulin delivery solutions. As a spin-off from Becton, Dickinson and Company, Embecta leverages innovative technologies and a comprehensive product portfolio—including insulin pens and syringes—to enhance patient care and health outcomes. Committed to operational excellence and customer-centric strategies, the company is strategically positioned to capitalize on growth opportunities in the fast-evolving diabetes care market. With a focus on improving patient experiences, Embecta aims to drive sustainable development and solidify its leadership in the industry.